retatrutide india | Triple Agonist Retatrutide effects greatest Weight Loss

In February 2022, the 46-year-old from New Jersey had prediabetes and high blood pressure when his doctor asked if he had considered trying a GLP-1 medication

Furthermore, in January 2025, the FDA approved semaglutide (Ozempic ) for reducing the risk of kidney failure and disease progression in patients with diabetes and chronic kidney disease (CKD), making it the first GLP-1 agent indicated for the treatment of CKD (Perkovic et al., 2024)

All 5 CVOTs reported reduction in hospitalization for HF, including DAPA-HF, which evaluated HF hospitalization and cardiovascular death as a composite primary outcome in patients with baseline chronic HF with reduced ejection fraction

Individual responses can vary between different GLP-1 receptor agonists

As demand, accessibility and affordability increase, its likely the number of users will rise and its important for them to be informed